Claims

1. Use of lixisenatide or/and a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of pediatric patients suffering from type 2 diabetes mellitus.

2. The use according to claim 1, wherein lixisenatide or/and the pharmaceutically acceptable salt thereof is to be administered as an add-on therapy to metformin or/and a pharmaceutically acceptable salt thereof.

3. The use according to claim 2, wherein metformin or/and the pharmaceutically acceptable salt thereof is prepared for oral administration.

4. The use according to any one of the preceding claims, wherein the patient in need of the pediatric treatment has an age of at least 10 years.

5. The use according to any one of the preceding claims, wherein the patient in need of the pediatric treatment has an age of less than 18 years.

6. The use according to any one of the preceding claims, wherein the patient in need of the pediatric treatment suffers from type 2 diabetes mellitus.

7. The use according to claim 6, wherein the type 2 diabetes mellitus has been diagnosed at least three months.

8. The use according to claim 6 or 7, wherein the type 2 diabetes mellitus is not adequately controlled by metformin monotherapy, by basal insulin monotherapy or by a combination of metformin and a basal insulin.

9. The use according to any one of the preceding claims, wherein the patient in need of the pediatric treatment is obese.

10. The use according to any one of the preceding claims, wherein the patient in need of the pediatric treatment has a body mass index of at least 30 kg/m^2 or at least 31 kg/m^2.

11. The use according to any one of the preceding claims, wherein lixisenatide is to be administered about 30 min before breakfast.

12. The use according to any one of the preceding claims, wherein at the onset of treatment with lixisenatide or/and the pharmaceutically acceptable salt thereof, the patient has a fasting plasma glucose concentration of at least 8 mmol/L or at least 8.5 mmol/L.

13. The use according to any one of the preceding claims, wherein at the onset of treatment with lixisenatide or/and the pharmaceutically acceptable salt thereof, the patient has a 2 hours postprandial plasma glucose concentration of at least 1 1.1 mmol/L or at least 12 mmol/L.

14. The use according to any one of the preceding claims, wherein at the onset of treatment with lixisenatide or/and the pharmaceutically acceptable salt thereof, the patient has a glucose excursion of at least 3 mmol/L, wherein the glucose excursion is the difference of the 2 hours postprandial plasma glucose concentration and plasma glucose concentration 30 minutes prior to a meal test.

15. The use according to any one of the preceding claims, wherein at the onset of treatment with lixisenatide or/and the pharmaceutically acceptable salt thereof, the patient has a HbA1 c value of at least about 7 %, at least about 7.5 %, at least about 8 %, at least about 8.5 %, at least about 8.65 %, or at least about 9%.